H.R. 8774House117th Congress (2021-2023)In Committee

Menopause Research Act of 2022

AI-Generated Summary

Updated February 8, 2026 at 5:23 PM UTC

The Menopause Research Act of 2022 directs the National Institutes of Health (NIH) to evaluate existing menopause‑related and mid‑life women’s health research, identify gaps in knowledge about causes, symptoms, and treatments, and develop a strategic plan to address those gaps. NIH must report its findings and plan to Congress within 180 days of enactment. The bill also authorizes $100 million for each of fiscal years 2023 and 2024 to fund this research. It impacts NIH, the Department of Health and Human Services, researchers, and women experiencing menopause.

Key Provisions

NIH must evaluate completed and ongoing menopause‑related and mid‑life women’s health studies, highlighting gaps in knowledge about causes, symptoms, and treatment safety/effectiveness.
NIH must calculate total NIH funding for menopause‑related research over the previous five fiscal years.
Within 180 days of enactment, NIH must submit a report of its evaluation and a strategic plan to close identified gaps and outline future research topics.
HHS, through NIH, is tasked with conducting or supporting menopause‑related and mid‑life women’s health research.
$100 million is authorized for each of fiscal years 2023 and 2024 to fund the activities required by the Act.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions

HouseCommittee Latest Action

Referred to the Subcommittee on Health.

Health Subcommittee

September 7, 2022

View full timeline

HouseIntro Referral

Introduced in House

September 6, 2022

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

September 6, 2022

HouseCommittee

Referred to the Subcommittee on Health.

Health Subcommittee

September 7, 2022

Bill Text

Latest available legislative text

Reading Mode

Raw Text PDF XML

Introduced in HouseIssued September 6, 2022

117th CONGRESS

2d Session

H. R. 8774

IN THE HOUSE OF REPRESENTATIVES

September 6, 2022

Mr. McKinley (for himself and Mrs. Axne) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To require the Director of the National Institutes of Health to conduct an evaluation of menopause-related research (including gaps in research and knowledge regarding the causes, symptoms, and treatments for menopause), to develop a strategic plan to resolve gaps in knowledge and research, and identify topics in need of further research relating to potential treatments for menopause-related symptoms, and for other purposes.

Short title

This Act may be cited as the Menopause Research Act of 2022.

Evaluation of menopause-related research

(a)

In general

The Director of the National Institutes of Health shall—

(1)

conduct an evaluation of—

(A)

the results of completed menopause-related research, and research on mid-life women’s health;

(B)

the status of ongoing menopause-related research, and research on mid-life women’s health; and

(C)

any gaps in knowledge and research on—

(i)

treatments for menopause-related symptoms; and

(ii)

the safety and effectiveness of treatments for menopause-related symptoms; and

(2)

as part of such evaluation, identify the total amount of funding allocated by the National Institutes of Health for the conduct or support of menopause-related research, and research on mid-life women’s health over the preceding 5 fiscal years.

(b)

Report; strategic plan

Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall submit to the Congress—

(1)

a report on the findings of such evaluation; and

(2)

a strategic plan—

(A)

to resolve the gaps in knowledge and research identified in the report; and

(B)

to identify topics in need of further research relating to potential treatments for menopause-related symptoms.

Menopause-related research, and research on mid-life women’s health

(a)

In general

The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct or support menopause-related research, and research on mid-life women’s health.

(b)

Authorization of appropriations

There is authorized to be appropriated to carry out this section $100,000,000 for each of fiscal years 2023 and 2024.